Alimera Sciences (ALIM) (NASDAQ:ALIM) is a pharmaceutical drug company focusing on ophthalmic diseases, which focuses around the area of the eye. It's best product candidate is Iluvien to treat diabetes patients that have a disease in their retina. Worldwide there are around 285 million diagnosed with diabetes. Thus, the company estimates 340,000 cases of this retinal disorder annually. The company does not expect to have any sales until the first quarter of 2011. 
The company faces risks from not being FDA approved in the three stage process. Furthermore, even if the drug is approved, the company has to market the product well. The product needs to be cost-effective and potential advantages over other products. 
The company's initial public offering of stock filed on the NASDAQ exchange on 2 November 2009. The proposed offer price range is $15.00-$17.00. The company is offering 6.0 million shares and raising $96 million. 
The company is pre-revenue with products coming to the market soon.